PA2G4 and glioblastoma: Moreover, patients with breast cancer who express high levels of PA2G4 have poor clinical outcomes42, and patients with GBM or pancreatic ductal adenocarcinoma who have high protein levels of p48 also have poor clinical outcomes6,43.